Cochrane · systematic review · CD014887
Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive bladder cancer
Lai, LY, Tafuri, SM, Ginier, EC, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
UrologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
3
No studies
2
Included studies
NR
No studies 2 · 40%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
NBI + WLC TURBT compared to WLC TURBT for transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
Population: transurethral resection of bladder tumors in people with suspected or diagnosed non‐muscle invasive bladder cancer
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Time to disease recurrence NBI + WLC TURBT vs WLC TURBT | HR 0.63 [0.45, 0.89] | 6 studies · 1244 participants | Low Downgraded: risk of bias, imprecision |
Time to disease progression NBI + WLC TURBT vs WLC TURBT | no estimate extracted | NR | No studies |
Major adverse event (Clavien‐Dindo grade III, IV, and V) NBI + WLC TURBT vs WLC TURBT | RR 1.77 [0.79, 3.96] | 4 studies · 1385 participants | Low Downgraded: risk of bias, imprecision |
Time to death from bladder cancer NBI + WLC TURBT vs WLC TURBT | no estimate extracted | NR | No studies |
Minor adverse event (Clavien‐Dindo grade I and II) NBI + WLC TURBT vs WLC TURBT | RR 0.88 [0.49, 1.56] | 4 studies · 1385 participants | Low Downgraded: risk of bias, imprecision |